Collegium Pharmaceutical Inc
Company Profile
Business description
Collegium Pharmaceutical Inc is a specialty pharmaceutical company. The company is engaged in developing and planning to commercialize abuse-deterrent products that incorporate its patented DETERx platform technology for the treatment of chronic pain and other diseases. The DETERx platform technology is designed to maintain the extended-release and safety profiles of abused drugs in the face of various methods including chewing, crushing, and dissolving. Its product portfolio includes Jornay, Xtampza ER, which is an abuse-deterrent, extended-release, oral formulation of oxycodone; and Nucynta Products, which are extended-release and immediate-release formulations of tapentadol; Belbuca, and Symproic.
Contact
100 Technology Center Drive
StoughtonMA02072
USAT: +1 781 713-3699
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - Specialty & Generic
Fiscal Year End
31 December 2025
Employees
357
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
---|---|---|---|
All Ordinaries | 8,828.70 | 56.70 | 0.65% |
CAC 40 | 7,738.42 | 75.83 | 0.99% |
DAX 40 | 23,790.11 | 116.82 | 0.49% |
Dow JONES (US) | 44,484.42 | 10.52 | -0.02% |
FTSE 100 | 8,774.69 | 10.64 | -0.12% |
HKSE | 24,221.41 | 149.13 | 0.62% |
NASDAQ | 20,393.13 | 190.24 | 0.94% |
Nikkei 225 | 39,762.48 | 223.85 | -0.56% |
NZX 50 Index | 12,784.29 | 49.76 | 0.39% |
S&P 500 | 6,227.41 | 29.40 | 0.47% |
S&P/ASX 200 | 8,597.70 | 56.60 | 0.66% |
SSE Composite Index | 3,454.79 | 2.95 | -0.09% |